The Emerging Role of [89Zr]Zr-DFO-Girentuximab PET/ CT in Accurate Characterisation and Staging of ccRCC: early experience with three Patients

被引：0
|
作者：
Gelardi, F. [1 ,2 ]
Antunovic, L. [2 ]
Larcher, A. [1 ,2 ]
Musso, G. [1 ,2 ]
Re, C. [1 ,2 ]
Cei, F. [1 ,2 ]
Belladelli, F. [1 ,2 ]
Salonia, A. [1 ,2 ]
Luciano, R. [1 ,2 ]
Tenace, N. [1 ,2 ]
Olivieri, M. [1 ,2 ]
Savi, A. [2 ]
Sollini, M. [1 ,2 ]
Chiti, A. [1 ,2 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-824
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 40 条
  • [31] [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
    Rosar, Florian
    Burgard, Caroline
    Larsen, Elena
    Khreish, Fadi
    Marlowe, Robert J.
    Schaefer-Schuler, Andrea
    Maus, Stephan
    Petto, Sven
    Bartholomae, Mark
    Ezziddin, Samer
    CANCER IMAGING, 2024, 24 (01)
  • [32] Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
    Verhoeff, S. R.
    Es, S.
    Boon, E.
    van Helden, E.
    Angus, L.
    Elias, S.
    Oosting, S.
    Aarntzen, E.
    Brouwers, A.
    Heskamp, S.
    Hoekstra, O. S.
    Verheul, H. M.
    Van der Veldt, A. A. M.
    de Vries, E. G. E.
    Boerman, O.
    van der Graaf, W. T. A.
    Oyen, W. J. G.
    van Herpen, C. M. L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] 89Zr-DFO-girentuximab PET/CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase 3 study
    Calais, Jeremie
    Shuch, Brian
    Pantuck, Allan
    Bernhard, Jean-Christophe
    Morris, Michael
    Master, Viraj
    Scott, Andrew
    van Praet, Charles
    Bailly, Clement
    Aksoy, Tamer
    Merkx, Robin
    Schuster, David
    Lee, Sze Ting
    Pandit-Taskar, Neeta
    Fan, Alice
    Tauchmanova, Libuse
    Allman, Phillip
    Schmidt, Karl
    Vadali, Kavita
    Hayward, Colin
    Mulders, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [34] In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET/MRI
    Schwenck, Johannes
    Sonanini, Dominik
    Seyfried, Dominik
    Ehrlichmann, Walter
    Kienzle, Gabriele
    Reischl, Gerald
    Krezer, Pascal
    Wilson, Ian
    Korn, Ron
    Gonzalez-Menendez, Irene
    Quintanilla-Martinez, Leticia
    Seith, Ferdinand
    Forschner, Andrea
    Eigentler, Thomas
    Zender, Lars
    Roecken, Martin
    Pichler, Bernd J.
    Flatz, Lukas
    Kneilling, Manfred
    la Fougere, Christian
    THERANOSTICS, 2023, 13 (08): : 2408 - 2423
  • [35] [89Zr]Df-crefmirlimab PET/CT imaging to assess the in vivo distribution of CD8+T-cells in hospitalized COVID-19 patients
    Aarntzen, E.
    Kouijzer, I.
    Peters, S.
    Lobeek, D.
    De Groot, M.
    de Veerdonk, F. Van
    Netea, M.
    Prokop, M.
    Prokop, M.
    Koenen, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S156 - S156
  • [36] Detection of HER2-positive metastases n patients with HER2-negative primary breast cancer using 89Zr-DFO-trastuzumab PET/CT
    Ulaner, Gary
    Hyman, David
    Ross, Dara
    Corben, Adriana
    Chandarlapaty, Sarat
    Goldfarb, Shari
    Heather, Mcarthur
    Erinjeri, Joseph
    Solomon, Stephen
    Kolb, Hartmuth
    Lyashchenko, Serge
    Lewis, Jason
    Carrasquillo, Jorge
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [37] Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+immune infiltrate with [89Zr] crefmirlimab berdoxam PET
    Amaral, Teresa
    Kneilling, Manfred
    Forschner, Andrea
    Leiter, Ulrike M.
    Schwenck, Johannes
    Kienzle, Gabriele
    Gueckel, Brigitte
    Sonanini, Dominik
    Reischl, Gerald
    Wilson, Ian
    Pichler, Bernd J.
    La Fougere, Christian
    Flatz, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
    Altena, R.
    Tzortzakakis, A.
    Blomgren, A.
    Jussing, E.
    Ekman, S.
    Tran, T.
    Axelsson, R.
    Bergh, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S402 - S403
  • [39] A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
    Margolin, K. A.
    Korn, R.
    Farwell, M.
    Postow, M. A.
    Hays, D.
    Wilson, I. A.
    Le, W. H.
    ANNALS OF ONCOLOGY, 2021, 32 : S930 - S930
  • [40] First-in-Human Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive malignancies
    Lohrmann, Christian
    O'Reilly, Eileen
    ODonoghue, Joseph
    Yu, Kenneth H.
    Pandit-Taskar, Neeta
    Lyashchenko, Serge
    Ruan, Shutian
    Wu, Jiong
    DeNoble, Phillip
    Carrasquillo, Jorge
    Schmidtlein, Charles
    Teng, Rebecca
    Lowery, Maeve A.
    Varghese, Anna
    Estrella, Hayley
    Scholz, Wolfgang
    Maffuid, Paul
    Lewis, Jason
    Weber, Wolfgang
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
1234